Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Summary:
- MACD is crossing MACD signal line at 0.7. MACD crossing signal line is bullish signal.
MarketCap | 3.2B |
---|---|
PE Ratio | -5.2 |
PEG Ratio | -3.0 |
P/B | 14.3 |
P/S (ttm) | 40.8 |
Earning Growth (QoQ) | |
Revenue Growth (QoQ) | |
Short % | 4% |
Held by Institutions % | 92% |
1 Day Vol Adjusted Return | -0.6 |
1 Month Vol Adjusted Return | 6.3 |
3 Month Vol Adjusted Return | -6.2 |
6 Month Vol Adjusted Return | -7.4 |
20 Days SMA Price ZScore | 0.4 |
50 Days SMA Price ZScore | -0.7 |
12 -26 Days PPO | -3.2 |
1 Month Average Short Volume Ratio | 40.6 |
1 Day Volume Change ZScore | -1.1 |
1 Month Daily Vol | 3.4 |
Stock news
PALO ALTO, Calif., January 30, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the U.S. Food and Drug Administration (FDA) has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic to identify advanced or metastatic breast cancer patients with ESR1 mutations who may benefit from treatment with ORSERDU™ (elacestrant), a nonsteroidal selective estrogen receptor degrader to be commercialized by Stemline Therapeutics, Inc., a
Guardant Health, Inc. ( NASDAQ:GH ) shareholders should be happy to see the share price up 16% in the last month. But...
The move comes about a month after the company's stock dropped by about 30% when it reported trial results of a test for colorectal cancer that disappointed some of its investors.
LONDON & PALO ALTO, Calif., January 19, 2023--TRACC Part C trial will use Guardant Reveal ctDNA blood test to evaluate opportunity to reduce unnecessary use of chemotherapy in colorectal cancer
PALO ALTO, Calif., January 17, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco.
PALO ALTO, Calif., January 09, 2023--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, today announced preliminary, unaudited results for the year ended December 31, 2022.
The charts of the oncology company are nothing but bearish and its stock could be in for more downside action ahead.
PALO ALTO, Calif., December 28, 2022--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference.
As we head into New Year 2023, we wanted to take a look at some of the top pharmaceutical blunders of the last several months. While many pharmaceutical stocks can hold immense profit potential, others can wipe out your accounts in the blink of an eye. That’s because – far too often — investors buy these stocks, which turn out to hold weak or non-existent pipelines. Or, investors will buy on the promise of unachieved growth. In fact, here are three that fit those molds, and should be sold headin
PALO ALTO, Calif. & DALLAS, December 21, 2022--Guardant Health & Susan G. Komen partner to develop studies to identify breast cancer patients who may benefit from additional monitoring or therapy.